BACKGROUND: von Willebrand factor (VWF) is synthesized by vascular endothelial cells and megakaryocytes. The VWF propeptide is critical for multimerization and acts as an intra-molecular chaperone for mature VWF in sorting to its storage organelles, Weibel-Palade bodies (WPBs). In the Canadian Type 3 VWD study, almost half of the identified variants were in the VWF propeptide and these were associated with an increased bleeding phenotype. OBJECTIVE: To investigate VWF propeptide variants that cause quantitative von Willebrand disease (VWD) by utilizing patient-derived endothelial colony-forming cells (ECFCs). PATIENTS/ METHODS: Endothelial colony-forming cells were isolated from five Type 3 VWD patients from four families with the following variants: (1) homozygous p.Asp75_Gly178del (deletion of exons 4 and 5 deletion; Ex4-5del), (2) homozygous p.Cys633Arg, (3) homozygous p.Arg273Trp, and (4) p.Pro293Glnfs*164 and p.Gln419* inherited in the compound heterozygous state. Additionally, ECFCs were isolated from six family members (two Type 1 VWD, four unaffected). RESULTS: Endothelial colony-forming cells from the Type 3 patient with the compound heterozygous genotype exhibited a true null VWF cellular phenotype, with negligible VWF detected. In contrast, the other three propeptide variants presented a similar expression pattern in homozygous ECFCs where VWF was synthesized but not packaged in WPBs, and variant VWF had an increased association with the endoplasmic reticulum (ER) marker, protein disulfide-isomerase (PDI), indicating an ER-retention phenotype. The biosynthetic phenotype was similar but to a lesser degree in heterozygous ECFCs expressing the non-null variants. CONCLUSION: This study further elucidates the importance of the VWF propeptide in the VWD phenotype using patient-derived cells.
BACKGROUND: von Willebrand factor (VWF) is synthesized by vascular endothelial cells and megakaryocytes. The VWF propeptide is critical for multimerization and acts as an intra-molecular chaperone for mature VWF in sorting to its storage organelles, Weibel-Palade bodies (WPBs). In the Canadian Type 3 VWD study, almost half of the identified variants were in the VWF propeptide and these were associated with an increased bleeding phenotype. OBJECTIVE: To investigate VWF propeptide variants that cause quantitative von Willebrand disease (VWD) by utilizing patient-derived endothelial colony-forming cells (ECFCs). PATIENTS/ METHODS: Endothelial colony-forming cells were isolated from five Type 3 VWD patients from four families with the following variants: (1) homozygous p.Asp75_Gly178del (deletion of exons 4 and 5 deletion; Ex4-5del), (2) homozygous p.Cys633Arg, (3) homozygous p.Arg273Trp, and (4) p.Pro293Glnfs*164 and p.Gln419* inherited in the compound heterozygous state. Additionally, ECFCs were isolated from six family members (two Type 1 VWD, four unaffected). RESULTS: Endothelial colony-forming cells from the Type 3 patient with the compound heterozygous genotype exhibited a true null VWF cellular phenotype, with negligible VWF detected. In contrast, the other three propeptide variants presented a similar expression pattern in homozygous ECFCs where VWF was synthesized but not packaged in WPBs, and variant VWF had an increased association with the endoplasmic reticulum (ER) marker, protein disulfide-isomerase (PDI), indicating an ER-retention phenotype. The biosynthetic phenotype was similar but to a lesser degree in heterozygous ECFCs expressing the non-null variants. CONCLUSION: This study further elucidates the importance of the VWF propeptide in the VWD phenotype using patient-derived cells.
Authors: J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici Journal: J Thromb Haemost Date: 2006-08-02 Impact factor: 5.824
Authors: Soundarya N Selvam; Lara J Casey; Mackenzie L Bowman; Lindsey G Hawke; Avery J Longmore; Jeffrey Mewburn; Mark L Ormiston; Stephen L Archer; Donald H Maurice; Paula James Journal: Blood Coagul Fibrinolysis Date: 2017-10 Impact factor: 1.276
Authors: Jiong-Wei Wang; Eveline A M Bouwens; Maria Carolina Pintao; Jan Voorberg; Huma Safdar; Karine M Valentijn; Hetty C de Boer; Koen Mertens; Pieter H Reitsma; Jeroen Eikenboom Journal: Blood Date: 2013-02-20 Impact factor: 22.113
Authors: Helmut W Ott; Andrea Griesmacher; Mirjam Schnapka-Koepf; Georg Golderer; Andrea Sieberer; Michael Spannagl; Burghardt Scheibe; Susanne Perkhofer; Kerstin Will; Ulrich Budde Journal: Am J Clin Pathol Date: 2010-02 Impact factor: 2.493
Authors: Javier Martin-Ramirez; Menno Hofman; Maartje van den Biggelaar; Robert P Hebbel; Jan Voorberg Journal: Nat Protoc Date: 2012-08-23 Impact factor: 13.491
Authors: P K Gupta; R Saxena; E Adamtziki; U Budde; F Oyen; T Obser; R Schneppenheim Journal: Blood Cells Mol Dis Date: 2008-05-16 Impact factor: 3.039
Authors: Grégoire Michaux; Lindsay J Hewlett; Sarah L Messenger; Anne C Goodeve; Ian R Peake; Martina E Daly; Daniel F Cutler Journal: Blood Date: 2003-06-05 Impact factor: 22.113